Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine, towards integrated management strategies

  • García-Castillo, María Clara
  • Sierra Mencia, Álvaro|||0000-0002-0022-6064
  • Caronna, Edoardo|||0000-0001-5525-0267
  • Toledo-Alfocea, Daniel|||0000-0003-3651-1614
  • Jaimes, Alex|||0000-0002-0890-9484
  • Urtiaga, Saray
  • Casas-Limón, Javier|||0000-0002-7353-4084
  • Muñoz-Vendrell, Albert|||0000-0001-8221-865X
  • Santos Lasaosa, Sonia|||0000-0002-4141-7705
  • García Martín, Valvanuz
  • Martín Ávila, Guillermo
  • Polanco Fernández, Marcos
  • Villar-Martínez, Maria Dolores|||0000-0003-3920-0176
  • Trevino-Peinado, Cristina|||0000-0001-8711-4884
  • Rubio-Flores, Laura|||0000-0001-5570-8055
  • Sánchez-Soblechero, Antonio|||0000-0002-7098-8494
  • Portocarrero Sánchez, Leonardo
  • Luque-Buzo, Elisa|||0000-0002-7983-9268
  • Lozano Ros, Alberto|||0000-0002-5186-8657
  • Gago-Veiga, Ana Beatriz|||0000-0002-0038-3406
  • Díaz de Terán, Javier|||0000-0003-0064-6269
  • Recio García, Andrea
  • Canales Rodríguez, Javiera
  • Gómez García, Andrea
  • González Salaices, Marta
  • Campoy Diaz, Sergio|||0000-0002-8135-4139
  • Mínguez-Olaondo, Ane|||0000-0002-7742-3920
  • Maniataki, Stefania
  • González-Quintanilla, Vicente|||0000-0003-0902-3906
  • Porta-Etessam, Jesús|||0000-0002-7034-682X
  • Cuadrado, María Luz|||0000-0001-8246-3743
  • Guerrero Peral, Ángel Luis|||0000-0001-7493-6002
  • Pozo-Rosich, Patricia|||0000-0003-0796-4702
  • Rodríguez-Vico, Jaime|||0000-0001-9360-5444
  • Huerta, Mariano|||0000-0003-0181-5335
  • Pascual Gómez, Julio|||0000-0002-3189-7573
  • Goadsby, Peter J.|||0000-0003-3260-5904
  • Gonzalez-Martinez, Alicia|||0000-0002-1228-1503
Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RE-START, Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine

  • Romero del Rincón, Celia|||0000-0002-0339-6616
  • Gonzalez-Martinez, Alicia|||0000-0002-1228-1503
  • Quintas, Sonia|||0000-0003-0622-8228
  • Garcia Azorin, David|||0000-0002-3132-1064
  • Fernández-Lázaro, Iris|||0009-0004-2544-5206
  • Guerrero Peral, Ángel Luis|||0000-0001-7493-6002
  • González Osorio, Yésica|||0000-0003-1461-9798
  • Santos Lasaosa, Sonia|||0000-0002-4141-7705
  • González Oria, Carmen
  • Sánchez Rodríguez, Norberto
  • Iglesias Díez, Fernando
  • Echavarría Íñiguez, Ana|||0000-0001-7038-2911
  • Gil Luque, Sendoa
  • Huerta, Mariano|||0000-0003-0181-5335
  • Campoy Diaz, Sergio|||0000-0002-8135-4139
  • Muñoz-Vendrell, Albert|||0000-0001-8221-865X
  • Lozano Ros, Alberto|||0000-0002-5186-8657
  • Sánchez-Soblechero, Antonio|||0000-0002-7098-8494
  • Velasco Juanes, Fernando
  • Kortazar-Zubizarreta, Izaro|||0000-0002-8107-660X
  • Echeverría, Amaya|||0000-0001-9225-5323
  • Rodríguez-Vico, Jaime|||0000-0001-9360-5444
  • Jaimes Sánchez, Alex
  • Gómez García, Andrea
  • Morollón Sánchez-Mateos, Noemí|||0000-0003-4256-4210
  • Belvís, Roberto|||0000-0002-2137-180X
  • Navarro Pérez, María Pilar|||0000-0001-6370-218X
  • García-Moncó, Juan Carlos
  • Álvarez Escudero, María Rocío
  • Montes, Nuria
  • Gago-Veiga, Ana Beatriz|||0000-0002-0038-3406
Background and purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAb) may be considered after 12-18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption. Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti-CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti-CGRP MAb (T-baseline); last month of first treatment period (T-suspension); month of restart due to worsening (T-worsening); and 3 months after resumption (T-reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD. Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T-baseline was 20 (13) and MMD was 5 (6); at T-suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T-worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T-reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001). Conclusion: The results suggest that anti-CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.